Indivior (NASDAQ:INDV) Trading Up 3%

Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) were up 3% during trading on Monday . The company traded as high as $19.89 and last traded at $19.89. Approximately 134,288 shares changed hands during mid-day trading, an increase of 12% from the average daily volume of 120,170 shares. The stock had previously closed at $19.32.

Analyst Ratings Changes

Separately, Craig Hallum started coverage on Indivior in a research note on Wednesday, April 3rd. They issued a "buy" rating and a $37.00 target price for the company.

Indivior Stock Up 2.2 %

The stock has a 50 day simple moving average of $20.35 and a 200 day simple moving average of $18.44. The company has a market capitalization of $2.72 billion, a price-to-earnings ratio of -986.51 and a beta of 0.46.

Indivior (NASDAQ:INDV - Get Free Report) last issued its earnings results on Thursday, February 22nd. The company reported $0.43 EPS for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. The company had revenue of $293.00 million during the quarter, compared to the consensus estimate of $260.00 million. Indivior had a return on equity of 538.18% and a net margin of 0.18%. As a group, analysts forecast that Indivior PLC will post 2.03 EPS for the current year.

Hedge Funds Weigh In On Indivior

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Scopia Capital Management LP acquired a new position in shares of Indivior during the third quarter worth approximately $191,743,000. Vanguard Group Inc. raised its holdings in Indivior by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company's stock worth $90,081,000 after purchasing an additional 52,836 shares in the last quarter. FMR LLC raised its holdings in Indivior by 53.5% during the third quarter. FMR LLC now owns 5,498,087 shares of the company's stock worth $119,339,000 after purchasing an additional 1,915,980 shares in the last quarter. Goldman Sachs Group Inc. bought a new stake in Indivior during the second quarter worth approximately $83,678,000. Finally, Barclays PLC raised its holdings in Indivior by 746.6% during the fourth quarter. Barclays PLC now owns 3,093,161 shares of the company's stock worth $47,232,000 after purchasing an additional 2,727,791 shares in the last quarter. 60.33% of the stock is currently owned by institutional investors and hedge funds.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.